Tonix Pharmaceuticals Presents Results of TNX-102 SL in P-III RELIEF study for the Management of Fibromyalgia at ASCP 2021 Published: June 4, 2021 | Tags: Tonix Pharmaceuticals, TNX-102 SL, P-III, RELIEF Study, Fibromyalgia, ASCP 2021 Dermavant Submits NDA to the US FDA for Tapinarof Cream to Treat Plaque Psoriasis Published: June 4, 2021 | Tags: […]Read More
Shots: The P-IIb VISION-DMD study involves assessing the efficacy & safety of vamorolone (2&6 mg/kg/day) vs PBO and prednisone (0.75 mg/kg/day) in 121 ambulant boys aged 4 to <7 years with DMD for 48 wks. The study met its 1EP i.e improvement in TTSTAND velocity, following the 1st period @24 wks. The 2 EPs include […]Read More
The biopharma industry saw numerous deal terminations in 2020. Clinical and regulatory results, change in control limitations, and strategic reprioritizations were among the most common reasons for deal termination. Sanofi and Hanmi’s agreement in 2015 ranked first under which Hanmi regained WW rights to its protein/peptide discovery technology, lapscovery. The second position goes to the […]Read More
Takeda Signs ~$1B Pact with Arrowhead for ARO-AAT Targeting Alpha-1 Antitrypsin-Associated Liver Disease Published: Oct 9, 2020 | Tags: Alpha-1 Antitrypsin-Associated Liver Disease, Arrowhead, Collaborates, Commercialize. ARO-AAT, Develop, Takeda, with Lilly and Incyte’s Olumiant (baricitinib) Reports Additional Data Demonstrating Reduction in COVID-19 Recovery Time Published: Oct 9, 2020 | Tags: COVID-19, Demonstrate, Incyte, Lilly, […]Read More
Shot: Santhera has discontinued the development of Puldysa (idebenone) in patients with DMD who are in respiratory decline and receive concomitant glucocorticoid treatment. The DSMB has recommended the discontinuation of the SIDEROS study due to futility as it fails to meet its 1EPs i.e. the change of FVC%p from baseline to 18mos. of treatment Following […]Read More
1. AbbVie to License I-Mab’s Lemzoparlimab (TJC4) for ~$2B Published: Sept 04, 2020 | Tags: AbbVie, License, I-Mab, Lemzoparlimab, (TJC4), ~$2B 2. Kite and HiFiBiO Therapeutics Collaborate to Develop Antibodies Targeting Acute Myeloid Leukemia Published: Sept 03, 2020 | Tags: Kite, HiFiBiO Therapeutics, Collaborate, Antibodies, Targeting, Acute Myeloid Leukemia 3. Abbott Initiates LIFE-BTK Trial to […]Read More
Shots: Idorsia transfers its development & commercialization agreement with ReveraGen to Santhera, whereby Santhera shall replace Idorsia as a party to the agreement. Santhera to get an exclusive license, including sublicensing rights, for vamorolone in all indications globally, including Japan and South Korea and a share in expected PR voucher In exchange for the revised […]Read More
Shots: Santhera to provide its lonodelestat and intellectual support for the scientists at CSHL who will conduct the non-clinical research program and validates hNE as a target and shed light on lonodelestat as a potential therapy against COVID-19 Researchers at CSHL are part of the consortium of international non/clinical experts called the ‘NETwork to target […]Read More
1. Lupin Launches Smart Device for Metered-Dose Inhalers to Support Treatment of Respiratory Diseases in India Published: Nov 22, 2019 | Tags: Lupin, Launches, Smart Device, Metered-Dose Inhalers, Support, Treatment, Respiratory Diseases, India 2. BioMarin Reports Submission of MAA to EMA for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A Published: Nov 21, 2019 | Tags: BioMarin, […]Read More
Shots: The SYROS study involves assessing of respiratory function evolution during periods of treatment with idebenone (900 mg/day) (On-Idebenone) compared to period without idebenone treatment (Off-Idebenone) in 18 patients with DMD not using glucocorticoids under Expanded Access Programs following P-III DELOS study, published in Neuromuscular Disorders The SYROS study results demonstrated long-term efficacy in slowing […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
